Animate Biosciences, Inc.
June 17, 2025
Company Presentation
Regenerative Medicine
154
At Animate Biosciences, we’re driven by a vision to outsmart one of the deadliest biological challenges: fibrosis. We have pioneered an innovative approach to amino acid-based therapeutics by integrating vast multi-omic data from nature's most effective regenerators, advancements in artificial intelligence and computing, and improvements in solid-phase peptide synthesis. This allows us to transition from in silico to in vitro testing of new peptides within two weeks. Our platform has produced two leading development candidates, each showing effectiveness in halting or reducing fibrosis in human skin, lung, cardiac, and liver cells. In vivo results for one of these compounds have demonstrated a reduction in fibrosis and aberrant cell growth. We are on track to finalize a peptide candidate and complete IND enabling studies for an orphan indication in dermatology in 2025.
Company HQ City:
Alameda
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
TGF receptor inhibitor
CEO
Peter Licari
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
Additional animal models currently being conducted
What is your next catalyst (value inflection) update?
July 2025
Website
animate.bio
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}